Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting now · Phase 2

Conditions studied: Prostate Cancer, Biochemical Recurrence

In brief

To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).

Key facts

Study ID
NCT05753566
Run by
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
People needed
96
Starts
2023-03-01
Expected to finish
2028-03-01
Last updated by the study team
2023-03-06

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.